Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission

M. T. van Lint, A. Bacigalupo, F. Frassoni, M. Repetto, G. Piaggio, M. Congiu, V. Vitale, D. Scarpati, P. Franzone, R. Corvò

Research output: Contribution to journalArticle

Abstract

Thirty-two patients with acute lymphoblastic leukemia (ALL) were given cyclophosphamide, 120 mg/kg, and total body irradiation (TBI), 10-12 Gy, followed by an allergic bone marrow transplant (BMT). Seven patients were in their first remission: 4 survived 8-24 months post-BMT and 3 died of BMT-related complications. Twenty-five patients were in their second remission: 12 survived, 7-50 months post-BMT. The actuarial survival for patients in 1st and 2nd CR is 57% and 40 %, respectively (p = 0.1). The overall survival for patients less than or older than 15 years of age is 73% and 50%, respectively (p = 0.2). The actuarial risk of relapse is currently 0% and 50% for 1st and 2nd CR patients (p = 0.06). Factors influencing relapse in 2nd CR patients are the length of first remission (p = 0.01), the severity of acute GvHD (p = 0.02), and the severity of chronic GvHD (p = 0.03). This study points out an age-dependent tolerance of transplant procedures in ALL, and a high relapse rate in 2nd remission patients, possibly influenced by the duration of first remission and the severity of GvHD.

Original languageEnglish
Pages (from-to)135-138
Number of pages4
JournalHaematologica
Volume71
Issue number2
Publication statusPublished - 1986

Fingerprint

Bone Marrow Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Transplants
Survival
Whole-Body Irradiation
Cyclophosphamide
Bone Marrow

ASJC Scopus subject areas

  • Hematology

Cite this

Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission. / van Lint, M. T.; Bacigalupo, A.; Frassoni, F.; Repetto, M.; Piaggio, G.; Congiu, M.; Vitale, V.; Scarpati, D.; Franzone, P.; Corvò, R.

In: Haematologica, Vol. 71, No. 2, 1986, p. 135-138.

Research output: Contribution to journalArticle

van Lint, MT, Bacigalupo, A, Frassoni, F, Repetto, M, Piaggio, G, Congiu, M, Vitale, V, Scarpati, D, Franzone, P & Corvò, R 1986, 'Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission', Haematologica, vol. 71, no. 2, pp. 135-138.
van Lint, M. T. ; Bacigalupo, A. ; Frassoni, F. ; Repetto, M. ; Piaggio, G. ; Congiu, M. ; Vitale, V. ; Scarpati, D. ; Franzone, P. ; Corvò, R. / Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission. In: Haematologica. 1986 ; Vol. 71, No. 2. pp. 135-138.
@article{bde3795cc2c74ca8bc3e2908ea8ab559,
title = "Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission",
abstract = "Thirty-two patients with acute lymphoblastic leukemia (ALL) were given cyclophosphamide, 120 mg/kg, and total body irradiation (TBI), 10-12 Gy, followed by an allergic bone marrow transplant (BMT). Seven patients were in their first remission: 4 survived 8-24 months post-BMT and 3 died of BMT-related complications. Twenty-five patients were in their second remission: 12 survived, 7-50 months post-BMT. The actuarial survival for patients in 1st and 2nd CR is 57{\%} and 40 {\%}, respectively (p = 0.1). The overall survival for patients less than or older than 15 years of age is 73{\%} and 50{\%}, respectively (p = 0.2). The actuarial risk of relapse is currently 0{\%} and 50{\%} for 1st and 2nd CR patients (p = 0.06). Factors influencing relapse in 2nd CR patients are the length of first remission (p = 0.01), the severity of acute GvHD (p = 0.02), and the severity of chronic GvHD (p = 0.03). This study points out an age-dependent tolerance of transplant procedures in ALL, and a high relapse rate in 2nd remission patients, possibly influenced by the duration of first remission and the severity of GvHD.",
author = "{van Lint}, {M. T.} and A. Bacigalupo and F. Frassoni and M. Repetto and G. Piaggio and M. Congiu and V. Vitale and D. Scarpati and P. Franzone and R. Corv{\`o}",
year = "1986",
language = "English",
volume = "71",
pages = "135--138",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission

AU - van Lint, M. T.

AU - Bacigalupo, A.

AU - Frassoni, F.

AU - Repetto, M.

AU - Piaggio, G.

AU - Congiu, M.

AU - Vitale, V.

AU - Scarpati, D.

AU - Franzone, P.

AU - Corvò, R.

PY - 1986

Y1 - 1986

N2 - Thirty-two patients with acute lymphoblastic leukemia (ALL) were given cyclophosphamide, 120 mg/kg, and total body irradiation (TBI), 10-12 Gy, followed by an allergic bone marrow transplant (BMT). Seven patients were in their first remission: 4 survived 8-24 months post-BMT and 3 died of BMT-related complications. Twenty-five patients were in their second remission: 12 survived, 7-50 months post-BMT. The actuarial survival for patients in 1st and 2nd CR is 57% and 40 %, respectively (p = 0.1). The overall survival for patients less than or older than 15 years of age is 73% and 50%, respectively (p = 0.2). The actuarial risk of relapse is currently 0% and 50% for 1st and 2nd CR patients (p = 0.06). Factors influencing relapse in 2nd CR patients are the length of first remission (p = 0.01), the severity of acute GvHD (p = 0.02), and the severity of chronic GvHD (p = 0.03). This study points out an age-dependent tolerance of transplant procedures in ALL, and a high relapse rate in 2nd remission patients, possibly influenced by the duration of first remission and the severity of GvHD.

AB - Thirty-two patients with acute lymphoblastic leukemia (ALL) were given cyclophosphamide, 120 mg/kg, and total body irradiation (TBI), 10-12 Gy, followed by an allergic bone marrow transplant (BMT). Seven patients were in their first remission: 4 survived 8-24 months post-BMT and 3 died of BMT-related complications. Twenty-five patients were in their second remission: 12 survived, 7-50 months post-BMT. The actuarial survival for patients in 1st and 2nd CR is 57% and 40 %, respectively (p = 0.1). The overall survival for patients less than or older than 15 years of age is 73% and 50%, respectively (p = 0.2). The actuarial risk of relapse is currently 0% and 50% for 1st and 2nd CR patients (p = 0.06). Factors influencing relapse in 2nd CR patients are the length of first remission (p = 0.01), the severity of acute GvHD (p = 0.02), and the severity of chronic GvHD (p = 0.03). This study points out an age-dependent tolerance of transplant procedures in ALL, and a high relapse rate in 2nd remission patients, possibly influenced by the duration of first remission and the severity of GvHD.

UR - http://www.scopus.com/inward/record.url?scp=0022980428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022980428&partnerID=8YFLogxK

M3 - Article

C2 - 3087834

AN - SCOPUS:0022980428

VL - 71

SP - 135

EP - 138

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 2

ER -